Be the first person to write a business review for TECHNE Corporation

Tekmira Pharmaceuticals is giving diseases the silent treatment. The biopharmaceutical company is attempting to develop therapies that inhibit or "silence" certain disease-causing genes through ribonucleic acid interference (RNAi), a mechanism that disrupts the production of proteins that can lead to cancer, metabolic, and infectious diseases. Tekmira's lead candidates are being developed to treat tumors and high cholesterol. It also partners with other pharmaceutical companies, such as Alnylam Pharmaceuticals and Roche, to advance additional RNAi products using Tekmira's stable nucleic acid-lipid particles (SNALP) RNAi drug delivery technology.

Tengion, Inc., a regenerative medicine company, focuses on discovering, developing, manufacturing, and commercializing a range of replacement organs and tissues, or neo-organs and neo-tissues to address unmet medical needs in urologic, renal, gastrointestinal and vascular diseases. It creates these functional neo-organs and neo-tissues using a patient’s own cells, or autologous cells, in conjunction with the company’s Organ Regeneration Platform. The company’s lead product candidate, the Neo-Urinary Conduit, is an autologous implant that catalyzes regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal, or cystectomy. Its product pipeline also includes various candidates in early stage development, such as Neo-Kidney Augment for patients with advanced chronic kidney disease, or CKD. The company was founded in 2003 and is headquartered in East Norriton, Pennsylvania.

Tercica, Inc. company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A. Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA.

Thallion Pharmaceuticals develops products for the treatment of cancer and infections. Thallion has three leading products in various developmental stages. The Shigamabs drug candidate is targeted to treat Shigatoxin producing E. coli infections. The company's TLN-232 is being evaluated as a treatment of a number of cancer conditions. Its TLN-4601 is another oncology focused treatment. Thallion was considering the possible sale of the company until it received a nearly $9 million capital infusion through an arrangement with Premium Brands. Though Thallion's operations didn't change, and it's still owned by the same shareholders, the move did take the company public.

Founded in 1929, the not-for-profit organization is a leading researcher of human diseases, their causes, and their potential cures. Much of its research into mammalian genetics is focused on mice, which share a similar genetic makeup to humans. In addition to its own research in areas such as cancer, immunology, and metabolic disease, the organization maintains colonies of mice and supplies them under the brand name JAX to other laboratories around the globe. Additionally, The Jackson Laboratory offers educational programs -- including internships, workshops, and predoctoral programs -- for both current and future scientists.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.